202 related articles for article (PubMed ID: 27057662)
21. CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era.
Hay KA; Turtle CJ
Immunotherapy; 2018 Feb; 10(4):251-254. PubMed ID: 29421980
[No Abstract] [Full Text] [Related]
22. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
23. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
24. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
25. CARs in chronic lymphocytic leukemia -- ready to drive.
Hosing C; Kebriaei P; Wierda W; Jena B; Cooper LJN; Shpall E
Curr Hematol Malig Rep; 2013 Mar; 8(1):60-70. PubMed ID: 23225251
[TBL] [Abstract][Full Text] [Related]
26. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
27. Advances in T-cell therapy for ALL.
Grupp SA
Best Pract Res Clin Haematol; 2014; 27(3-4):222-8. PubMed ID: 25455270
[TBL] [Abstract][Full Text] [Related]
28. The what, when and how of CAR T cell therapy for ALL.
Frey N
Best Pract Res Clin Haematol; 2017 Sep; 30(3):275-281. PubMed ID: 29050700
[TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptor T cell therapy: 25years in the making.
Gill S; Maus MV; Porter DL
Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053
[TBL] [Abstract][Full Text] [Related]
30. [Advances of treatment study on acute lymphoblastic leukemia with chimeric antigen receptor modified T cells].
Weng WW; Tang YM
Zhonghua Er Ke Za Zhi; 2019 Aug; 57(8):643-646. PubMed ID: 31352754
[TBL] [Abstract][Full Text] [Related]
31. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.
Lorentzen CL; Straten PT
Scand J Immunol; 2015 Oct; 82(4):307-19. PubMed ID: 26099639
[TBL] [Abstract][Full Text] [Related]
32. Strategies to genetically engineer T cells for cancer immunotherapy.
Spear TT; Nagato K; Nishimura MI
Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
[TBL] [Abstract][Full Text] [Related]
33. Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.
Ruella M; June CH
Curr Hematol Malig Rep; 2016 Oct; 11(5):368-84. PubMed ID: 27475429
[TBL] [Abstract][Full Text] [Related]
34. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
36. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.
Hammill JA; Afsahi A; Bramson JL; Helsen CW
Methods Mol Biol; 2016; 1458():137-57. PubMed ID: 27581020
[TBL] [Abstract][Full Text] [Related]
37. Engineered cell therapy for cancer gets thumbs up from FDA advisers.
Ledford H
Nature; 2017 Jul; 547(7663):270. PubMed ID: 28726836
[No Abstract] [Full Text] [Related]
38. Chimeric antigen receptor T-cell therapy for ALL.
Maude SL; Shpall EJ; Grupp SA
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):559-64. PubMed ID: 25696911
[TBL] [Abstract][Full Text] [Related]
39. Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia.
Cao J; Cheng H; Shi M; Wang G; Chen W; Qi K; Li H; Qiao J; Zhao J; Wu Q; Zeng L; Jing G; Zheng J; Xu K
Leukemia; 2019 Nov; 33(11):2751-2753. PubMed ID: 31308471
[No Abstract] [Full Text] [Related]
40. [Monoclonal antibodies BCA-16 against surface T-cell antigen in healthy persons and in patients with leukemia].
Bulycheva TI; Novikova NN; Miterev GIu; Novikova MS
Gematol Transfuziol; 1988 Dec; 33(12):45-7. PubMed ID: 3266166
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
